Looking to establish a “hub” in the cell therapy ecosystem, the Novo Nordisk Foundation is pumping 950 million Danish kroner (about $136 million) into a new clinical production site at the Technical University of Denmark (DTU) in Lyngby.Dubbed the Cellerator, the facility will cater to public and private clients in academia, biotech and the pharmaceutical industry.

为了在细胞治疗生态系统中建立一个“枢纽”，诺和诺德基金会正在Lyngby的丹麦技术大学（DTU）将9.5亿丹麦克朗（约1.36亿美元）泵入一个新的临床生产基地。该设施将为学术界，生物技术和制药业的公私客户提供服务。

Construction is due to kick off next summer, and the site is expected to be operational in 2027, the Novo Nordisk Foundation said in a release.The center is being established to bridge a 'critical gap' in the current cell therapy ecosystem, Thomas H.R. Carlsen, CEO of the Cellerator, said in an interview.As it stands, many cell therapies that undergo successful testing in the lab don’t make it to human trials, Carlsen said.

诺和诺德基金会在一份发布中表示，该建筑将于明年夏季启动，预计该场地将于2027年投入运营。Cellerator首席执行官Thomas H.R.Carlsen在一次采访中说，该中心正在建立，以弥合当前细胞治疗生态系统中的“关键差距”。就目前而言，许多在实验室中成功测试的细胞疗法并没有进入人体试验阶段，Carlsen说。

That’s because those therapeutics are difficult to develop and manufacture at scale.That's where the Novo Nordisk Foundation is stepping in. The Cellerator will be used to advance testing on cell therapies that have gone through successful testing in animals plus to manufacture those therapies “consistently and at scale for early clinical trials,” the foundation said.The group plans to support a range of cell therapy types, including those derived from embryonic stem cells, pluripotent stem cells and adult stem cells.

这是因为这些疗法难以大规模开发和制造。这就是诺和诺德基金会正在介入的地方。基金会说，Cellerator将用于推进细胞疗法的测试，这些疗法已经在动物身上进行了成功的测试，并“为早期临床试验提供一致和规模的制造这些疗法”。该小组计划支持一系列细胞治疗类型，包括源自胚胎干细胞，多能干细胞和成体干细胞的细胞治疗类型。

The Cellerator's service offerings will run the gamut from process development and manufacturing to product release and regulatory support.The site's footprint is set to cover 5,000 square meters (53,820 square feet), Carlsen said. That includes both development laboratories for process development plus space for manufacturing, he said.As it stands, the Cellerator has “just shy” of 10 employees who are specialized in cell therapy development and manufacturing, Carlsen said.

Cellerator的服务产品将从流程开发和制造到产品发布和监管支持。卡尔森说，该网站的占地面积将覆盖5000平方米（53820平方英尺）。他说，这包括过程开发开发实验室和制造空间。卡尔森说，就目前而言，Cellerator只有10名专门从事细胞疗法开发和制造的员工“只是害羞”。

T.

吨。

Related

相关的

BlueWhale Bio surfaces with $18M on mission to overhaul cell therapy production

BlueWhale生物表面，需要1800万美元才能进行全面的细胞疗法生产

Right now, however, there is a “major workforce gap within the field,' the CEO added. The foundation hopes to resolve staffing issues through its partnership with the DTU.The Cellerator is poised to become the first large-scale production site for cell therapies in Denmark, where a few hospitals already have small-scale facilities for production.

然而，首席执行官补充说，目前“该领域存在严重的劳动力差距”。基金会希望通过与DTU的合作解决人员配置问题。该Cellerator有望成为第一个大规模生产基地。丹麦的细胞疗法，一些医院已经有小规模的生产设施。

Aside from filling a gap in the Danish cell therapy ecosystem, the Cellerator will cater to international clients, too, the foundation said.Novo is touting the facility as a potential “knowledge hub for Denmark and Europe,” and the foundation has already started forming partnerships around the site.The Cellerator will be rolled out as a limited liability company fully owned and funded by the Novo Nordisk Foundation and operated as an independent philanthropic initiative..

基金会表示，除了填补丹麦细胞治疗生态系统的空白之外，细胞治疗师还将照顾国际客户。Novo将该设施吹捧为潜在的“丹麦和欧洲的知识中心”，基金会已经开始在该网站周围建立合作伙伴关系。Cellerator将作为由诺和诺德基金会完全拥有和资助的有限责任公司推出，并作为独立慈善计划运营。。

Related

相关的

Bristol Myers Squibb partners with Cellares for robotic production of pipeline CAR-T drug

百时美施贵宝与酒窖合作，用于机器人生产管道CAR-T药物

As a spinout of the foundation, much of the cash generated by the Cellerator will be reinvested in the company, Carlsen said.

卡尔森说，作为基金会的一部分，Cellerator产生的大部分现金将在公司重新投资。